Paul Carter’s Post

It's a harsh reality that countless promising healthcare breakthroughs never see the light of day. At Aditxt, we're committed to rewriting that narrative. We're excited to have had the opportunity to showcase our mission on Benzinga this week: discovering, developing, and actualizing breakthrough innovations. Dive into CEO Amro Albanna's interview below.

I am so proud to be part of a team that holds science innovation at the forefront of their business model! Ask me today how our humanized animal models can accelerate your preclinical research. #cancer #humanizedmice #oncology #AACR #immunology

 Exogenus Therapeutics secures strategic funding.  We're thrilled to announce a strategic investment led by 3xP Global, which will boost the development of #Exo-101, a promising biological medicine derived from umbilical cord blood, for regenerative medicine and inflammatory disorders. This investment will be used for scaling-up of production capabilities towards GMP standards, helping to bridge the gap from pre-clinical to clinical stages, positioning us one step closer to reach patients in need. It will also support team growth and expansion of Exogenus Therapeutics pipeline to reach other markets. Find out more about Exogenus Therapeutics at www.exogenus-t.com #ExogenusTherapeutics #3xPGlobal #Biotech #Innovation #HealthCareInvestement

Optimized Molecules for Optimized Profiles: An AI-Driven Platform for Small Molecule Drug Discovery with Fred Manby from Iambic Therapeutics. Iambic has created a cutting-edge AI-driven platform to tackle the most challenging design problems in drug discovery and address unmet patient need. Our platform enables us to widely explore chemical space, while also sampling a wide range of target product profiles. We have demonstrated our platform on initial programs, with our first scheduled for clinical entry just two years after launch. https://lnkd.in/eDBzUurr Save $150 with Discount code SPK150. #drugdiscoverychemistry

Our CDO, Pascal Merchiers and Scientist, Laust Bavnhøj, are at the Antibody Engineering & Therapeutics Europe Conference in London this week.    If you are attending and would like to find out about Commit Biologics' BiCE™ Technology Platform and how it can supercharge a conventional monoclonal #antibody to activate the #ComplementSystem, please reach out.   To learn more, visit our website through the link in our comments below.   #AntibodyEngineeringandTherapeuticsEurope2024 #ImmuneResponse #ImmuneSystem #BiCEtechnology  

Exogenus Therapeutics secures strategic funding through 3xP Global. This investment will boost the development of Exo-101, a promising biological medicine derived from umbilical cord blood, for regenerative medicine and inflammatory disorders. This investment will be used for scaling production capabilities towards GMP standards, helping to bridge the gap from pre-clinical to clinical stages, and positioning us one step closer to reaching patients in need. It will also support team growth and expansion of the Exogenus pipeline to reach other markets. Miguel Lemos, Board Member of 3xP Global adds, “Exogenus has been paving the way for the therapeutic usage of extracellular vesicle-based products. It has the recognition of some of the top-rating pharma players in this field. In 3xP we are very happy to be part of this project, led by Joana Simões Correia, and supported by a heartened and dedicated team". 👌 Find out more here https://lnkd.in/dtR3Dg_z #ExogenusTherapeutics #3xPGlobal #Biotech #Innovation #HealthCareInvestement #biologicalmedicine

Join Vector Laboratories, Inc. for an exciting webinar regarding influencing ADC performance through linker design. Register below and set a reminder for May 21st at 2pm EDT! Don't miss out! #lifescience #ADC #biotechnology

Iambic Therapeutics Elevates AI-Driven Drug Discovery with $100M Boost San Diego-based biotech firm Iambic Therapeutics, formerly known as Entos, has secured $100 million in Series B financing. The funding round was led by Ascenta Capital and Abingworth, with participation from investors like NVIDIA, Illumina Ventures, and Gradiant Corporation, among others. The funds will be utilized to advance multiple drug candidates into clinical trials, expand the drug pipeline, enhance AI and automation technologies for drug discovery, and integrate NVIDIA technology for faster discovery processes. Iambic focuses on AI-driven drug discovery, combining physics-based machine learning with experimental automation, resulting in unique therapeutic candidates such as IAM-H1, a brain-penetrant HER2 inhibitor, and IAM-C1, a dual CDK2/4 inhibitor addressing treatment resistance in malignancies. #IambicTherapeutics #BiotechFirm #SeriesBFinancing #AscentaCapital #Abingworth #NVIDIA #IlluminaVentures #GradiantCorporation #AIinDrugDiscovery #ClinicalTrials #DrugPipeline #AIandAutomation #NVIDIATechnology #DrugDiscovery #MachineLearning #ExperimentalAutomation #IAMH1 #IAMC1 #HER2Inhibitor #CDK2Inhibitor #TreatmentResistance #TherapeuticCandidates #Biotechnology #MedicalInnovation